Rhodes Pharmaceuticals, L.P.

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Rhodes Pharmaceuticals, L.P. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed later-stage tilt top decile by trial count

Rhodes Pharmaceuticals, L.P.: 10 sponsored US clinical trials, none currently recruiting.

Rhodes Pharmaceuticals, L.P. sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 9 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is ADHD, with 2 trials.

Top-decile sponsor footprint

Rhodes Pharmaceuticals, L.P. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 4

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

NCT02470234
COMPLETED Phase 4

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

NCT02683265
COMPLETED Phase 3

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

NCT02555150
COMPLETED Phase 3

PRC-063 in an ADULT Workplace Environment

NCT02225639
COMPLETED Phase 3

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

NCT02168127
COMPLETED Phase 3

PRC-063 in Adolescent ADHD

NCT02139111
COMPLETED Phase 3

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

NCT02139124
COMPLETED Phase 1

Safety and Efficacy of PG101 for Dry Eye Syndrome

NCT02078661
COMPLETED Phase 3

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
COMPLETED Phase 3

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

NCT01239030

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 7
Phase 4 2

Therapeutic Areas

ADHD 2
Attention Deficit Hyperactivity Disorder (ADHD) 1
Attention Deficit Hyperactivity Disorder 1

How the Rhodes Pharmaceuticals, L.P. archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 9 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: ADHD (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Rhodes Pharmaceuticals, L.P.: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Rhodes Pharmaceuticals, L.P. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Rhodes Pharmaceuticals, L.P.Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Rhodes Pharmaceuticals, L.P. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rhodes Pharmaceuticals, L.P. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Rhodes Pharmaceuticals, L.P. page

10 registered trials is a research-attention snapshot, not an endorsement of Rhodes Pharmaceuticals, L.P. or any single study.

  • None of Rhodes Pharmaceuticals, L.P.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • ADHD is the condition Rhodes Pharmaceuticals, L.P. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See ADHD trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Rhodes Pharmaceuticals, L.P. pipeline card: 10 registered trials from official public datasets.Report a data error.